# A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

> **NCT06703606** · PHASE1 · RECRUITING · sponsor: **Pfizer** · enrollment: 15 (estimated)

## Conditions studied

- Severe Hemophilia A

## Interventions

- **DRUG:** MARSTACIMAB

## Key facts

- **NCT ID:** NCT06703606
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-13
- **Primary completion:** 2027-05-05
- **Final completion:** 2027-05-05
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06703606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06703606, "A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06703606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*